Quantification of trace 227Ac and other radionuclidic impurities in mass-separated 225Ac samples produced at CERN-MEDICIS

Abstract 225Ac is a promising candidate medical radionuclide for targeted alpha therapy of advanced stage cancers. One of the main production pathways is the high-energy proton spallation of thorium-based targets, that requires an efficient, nuclide-selective separation method to recover 225Ac from...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Jake D. Johnson, Cyril Bernerd, Frank Bruchertseifer, Thomas E. Cocolios, Marie Deseyn, Charlotte Duchemin, Michael Heines, Max Keppens, Laura Lambert, Nathan Meurrens, Ralf E. Rossel, Thierry Stora, Viktor Van den Bergh
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Nature Portfolio 2025-07-01
Serie:	Scientific Reports
Accesso online:	https://doi.org/10.1038/s41598-025-02277-4
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!